# UNITED STATES PATENT AND TRADEMARK OFFICE

### BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO., LTD., CELLTRION INC, and BIOCON BIOLOGICS INC.

Petitioners,

v.

REGENERON PHARMACEUTICALS, INC., Patent Owner.

Patent No. 11,253,572

Inter Partes Review No. IPR2023-008841

PATENT OWNER'S UPDATED MANDATORY NOTICES

<sup>&</sup>lt;sup>1</sup> IPR2024-00260 and IPR2024-00298 are joined with IPR2023-00884.



**B**.

Patent Owner, Regeneron Pharmaceuticals, Inc., hereby files mandatory notices pursuant to 37 C.F.R. § 42.8(a)(3).

A. Real Party-in-Interest (37 C.F.R. § 42.8(b)(1)) – unchanged

The real party-in-interest is Regeneron Pharmaceuticals, Inc.

Related Matters (37 C.F.R. § 42.8(b)(2)) – unchanged

In accordance with the Office Patent Trial Practice Guide (77 Fed. Reg. 48756, at 48759-60 (Aug. 14, 2012)), Patent Owner identifies the following related matters:

U.S. Patent No. 11,253,572 was previously challenged in *Apotex Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2022-01524 (P.T.A.B.).

Related U.S. Patent No. 10,888,601 was challenged in *Mylan*Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc., Case No. IPR202201226 (P.T.A.B.), which was joined with IPR2023-00533 and IPR2023-00566.

Patent Owner has appealed the Board's decision in IPR2022-01226 to the Federal Circuit in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 24-1567 (Fed. Cir.). U.S. Patent No. 10,888,601 is also being challenged in Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc., Case No. IPR2023-00739 (P.T.A.B.) and in Biocon Biologics Inc. v. Regeneron Pharmaceuticals, Inc., Case No. IPR2024-00201 (P.T.A.B.), which has been joined with IPR2023-00739.



Related U.S. Patent No. 10,130,681 was challenged in *Mylan*Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc., Case No. IPR202201225 (P.T.A.B.), which was joined with IPR2023-00532. Patent Owner has appealed the Board's decision in IPR2022-01225 to the Federal Circuit in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 24-1564 (Fed. Cir.). U.S. Patent No. 10,130,681 is also being challenged in Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc., Case No. IPR2023-00442 (P.T.A.B.).

Related patents U.S. Patent Nos. 9,669,069 and 9,254,338 were challenged in *Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2021-00880 (P.T.A.B.) and in *Mylan Pharmaceuticals Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2021-00881 (P.T.A.B.), respectively. IPR2021-000880 was joined with IPR2022-00257 and IPR2022-00301. IPR2021-00881 was joined with IPR2022-00258 and IPR2022-00298. Patent Owner has appealed the Board's decisions in those cases to the Federal Circuit, in *Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.*, No. 2023-1395 (Fed. Cir.) and *Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.*, No. 2023-1396 (Fed. Cir.), respectively.

U.S. Patent No. 11,253,572 and related patents have been asserted in Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 1:22-cv-



00061-TSK (N.D. W.Va.); Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc., No. 1:23-cv-00089-TSK (N.D. W.Va.); Regeneron Pharmaceuticals, Inc. v. Samsung Biopeis, Co., Ltd., No. 1:23-cv-00094-TSK (N.D. W.Va.); Regeneron Pharmaceuticals, Inc. v. Formycon AG, No. 1:23-cv-00097-TSK (N.D. W.Va.); Regeneron Pharmaceuticals, Inc. v. Samsung Biopeis, Co., Ltd., No. 1:23-cv-00106-TSK (N.D. W.Va.); and Regeneron Pharmaceuticals, Inc. v. Amgen, Inc. 2:24-cv-00264 (C.D. Cal.).

Out of abundance of caution, Patent Owner further identifies *Chengdu Kanghong Biotechnology Co. v. Regeneron Pharms., Inc.*, Case No. PGR2021-00035 (P.T.A.B.) (proceeding terminated) regarding related U.S. Patent No. 10,828,345.

Out of an abundance of caution, Patent Owner further identifies *Apotex Inc. v. Regeneron Pharmaceuticals, Inc.*, Case No. IPR2023-00099 (P.T.A.B.) (proceeding terminated), regarding related U.S. Patent No. 10,857,205, which Regeneron disclaimed.

Patent Owner does not concede that the identified matters would affect, or be affected by, a decision in the present *Inter Partes* Review of U.S. Patent No. 11,253,572.



# C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)) – UPDATED

Lead Counsel	Backup Counsel
Adam R. Brausa	Rebecca Weires
Reg. No. 60,287	Reg. No. 77,895
MORRISON & FOERSTER LLP	MORRISON & FOERSTER LLP
425 Market Street	425 Market Street
San Francisco, California 94105	San Francisco, California 94105
Tel: (415) 268-6053	Tel: (415) 268-6028
Fax: (415) 268-7522	Fax: (415) 268-7522
ABrausa@mofo.com	RWeires@mofo.com
Backup Counsel	Backup Counsel
Kira A. Davis	Daralyn J. Durie
(pro hac vice, granted)	(pro hac vice, granted)
MORRISON & FOERSTER LLP	MORRISON & FOERSTER LLP
707 Wilshire Blvd., Suite 6000	425 Market Street
Los Angeles, California 90017	San Francisco, California 94105
Tel: (213) 892-5654	Tel: (415) 268-6055
Fax: (213) 892-5454	Fax: (415) 268-7522
<u>KiraDavis@mofo.com</u>	DDurie@mofo.com
Backup Counsel (NEW)	Backup Counsel (NEW)
Matthew M. Wilk	Jeremy Cobb
(pro hac vice, to be filed)	(pro hac vice, to be filed)
Arnold & Porter Kaye Scholer LLP	Arnold & Porter Kaye Scholer LLP
250 West 55th Street	601 Massachusetts Ave, NW
New York, NY 10019-9710	Washington, DC 20001-3743
Tel: (212) 836-7152	Tel: (202) 942-6828
Fax: (212) 836-8689	Fax: (202) 942-5999
matthew.wilk@arnoldporter.com	jeremy.cobb@arnoldporter.com



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

